Yonsei, REPUBLIC OF KOREA - 30 Aug `18Investigation on the Expression of HMGB1

Official Title: The Investigation on the Expression of High Mobility Group Protein Box-1 (HMGB1) in Peripheral Blood of Vitiligo Patients and Healthy Controls According to Clinical Features, Treatment and Disease Activity

In Brief: Vitiligo is an acquired depigmented disorder that causes white spots on the skin due to the loss of melanocytes. It is a common disease which accounts for 0.5-1% of the whole population. It is a refractory skin disease with 25-50 thousand patients in Korea. And it is often caused in the exposed areas of the patient, causing a great deal of mental and social dysfunction in the patient's life, and may lead to suicide attempts.

Ages Eligible: 19 Years and older

Start Date: August 30, 2018

Completion Date (estimated): August 29, 2020

Status: Active, recruiting

Study ID from ClinicalTrials.gov: NCT03741738

Location: Department of Dermatology, Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea, 03722

Contact: To learn more about this study, you or your doctor may contact Sang Ho Oh, MD, PhD by phone +82 2 2228 2080 or email oddung93@yuhs.ac. Please refer to this study by its NCT number.

Back

FAQOther Questions

  • What tests should be done?

    A well-trained dermatologist should be able to diagnose vitiligo and distinguish it from contact leukoderma or more than twenty other conditions with similar skin appearance bas...

  • How to get insurance coverage for vitiligo treatments?

    Vitiligo insurance coverage is a pretty convoluted topic. To make things as clear and straightforward as possible, we've turned the key facts into this easy-to-digest Q&A fo...

  • PTSD in Vitiligo?

    Living with vitiligo often involves dealing with more than just skin changes. Many people with vitiligo face discrimination, social stigma, and isolation, which can lead to lowe...